caa a22 4500 463255542 CHVBK 20180405153354.0 cr unu---uuuuu 170326e20070601xx s 000 0 eng 10.1007/s00277-007-0275-9 doi (NATIONALLICENCE)springer-10.1007/s00277-007-0275-9 Enhanced expression of the nuclear envelope LAP2 transcriptional repressors in normal and malignant activated lymphocytes [Elektronische Daten] [Raz Somech, Einav Nili Gal-Yam, Sigal Shaklai, Orit Geller, Ninette Amariglio, Gideon Rechavi, Amos Simon] Extensive research in recent years has broadened the functions of nuclear envelope proteins beyond simply stabilizing the nucleus architecture. Particularly, integral nuclear membrane proteins, such as the alternative spliced isoforms of lamina-associated polypeptide 2 (LAP2), have been shown to be important for the initiation of replication and repression of transcription. The latter is regulated by epigenetic changes, induced by the binding of LAP2β to histone deacetylase-3 (HDAC3), resulting in histone H4 deacetylation. Involvement of nuclear envelope proteins in pathological proliferative conditions, mainly those involving abnormal recruitment and activation of HDACs, is still unknown. In this paper, we show that various nuclear envelope proteins are highly expressed in normal and malignant activated lymphocytes. Specifically, rapidly replicating cells of various hematological malignancies highly express LAP2β, while slowly proliferating malignant cells of chronic malignant hematological diseases do not. Taking together the elevated expression of LAP2β in highly proliferative malignant cells with its known ability to modify histones through binding with HDAC3 raises the possibility of its role in hematological malignancies involving aberrant activity of HDAC3. Based on our presented results, we believe that the LAP2-HDAC regulatory pathway should be studied as a new target for rational therapy. Springer-Verlag, 2007 LAP2 nationallicence HDAC3 nationallicence Transcriptional repression nationallicence Nuclear envelope nationallicence Epigenetic histone modifications nationallicence Somech Raz Sheba Cancer Research Center, Institute of Hematology, Chaim Sheba Medical Center, Tel-Hashomer, Israel aut Nili Gal-Yam Einav Sheba Cancer Research Center, Institute of Hematology, Chaim Sheba Medical Center, Tel-Hashomer, Israel aut Shaklai Sigal Sheba Cancer Research Center, Institute of Hematology, Chaim Sheba Medical Center, Tel-Hashomer, Israel aut Geller Orit Sheba Cancer Research Center, Institute of Hematology, Chaim Sheba Medical Center, Tel-Hashomer, Israel aut Amariglio Ninette Sheba Cancer Research Center, Institute of Hematology, Chaim Sheba Medical Center, Tel-Hashomer, Israel aut Rechavi Gideon Sheba Cancer Research Center, Institute of Hematology, Chaim Sheba Medical Center, Tel-Hashomer, Israel aut Simon Amos Sheba Cancer Research Center, Institute of Hematology, Chaim Sheba Medical Center, Tel-Hashomer, Israel aut Annals of Hematology Springer-Verlag 86/6(2007-06-01), 393-401 0939-5555 86:6<393 2007 86 277 https://doi.org/10.1007/s00277-007-0275-9 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00277-007-0275-9 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Somech Raz Sheba Cancer Research Center, Institute of Hematology, Chaim Sheba Medical Center, Tel-Hashomer, Israel aut NATIONALLICENCE 700 1- Nili Gal-Yam Einav Sheba Cancer Research Center, Institute of Hematology, Chaim Sheba Medical Center, Tel-Hashomer, Israel aut NATIONALLICENCE 700 1- Shaklai Sigal Sheba Cancer Research Center, Institute of Hematology, Chaim Sheba Medical Center, Tel-Hashomer, Israel aut NATIONALLICENCE 700 1- Geller Orit Sheba Cancer Research Center, Institute of Hematology, Chaim Sheba Medical Center, Tel-Hashomer, Israel aut NATIONALLICENCE 700 1- Amariglio Ninette Sheba Cancer Research Center, Institute of Hematology, Chaim Sheba Medical Center, Tel-Hashomer, Israel aut NATIONALLICENCE 700 1- Rechavi Gideon Sheba Cancer Research Center, Institute of Hematology, Chaim Sheba Medical Center, Tel-Hashomer, Israel aut NATIONALLICENCE 700 1- Simon Amos Sheba Cancer Research Center, Institute of Hematology, Chaim Sheba Medical Center, Tel-Hashomer, Israel aut NATIONALLICENCE 773 0- Annals of Hematology Springer-Verlag 86/6(2007-06-01), 393-401 0939-5555 86:6<393 2007 86 277 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer